Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Pharma Industry Lays Out Wishlist For New Government, Proposes Five-Year Pact

Executive Summary

The French pharmaceutical industry association is cautiously optimistic that the new government will take a longer-term view of the industry’s contribution to healthcare, and has proposed a pact setting out the relations between the industry and the state.

You may also be interested in...



French Govt Has The Chance To Act Now To Boost Pharma Prospects, Says Industry Body

Sales growth is slowing, innovation is being impaired, and prices remain constrained in France, says the industry body Leem. It has called on the government to take urgent action to remedy the situation.

France’s New President Will Support A Pharma Industry That Produces Innovation At Fair Prices

Emmanuel Macron, who will be sworn in as the new French president on May 14, is likely to promulgate pro-industry policies, although he has warned that innovation in medicines must come at a “fair price.”

France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund

The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS120798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel